2019
Eugene Sobngwi; Liliane Mfeukeu-Kuate; Merveille Kouam; Aurel T Tankeu; Chris N Nganou-Gnindjio; Ba Hamadou; Martine Etoa; Eliane Ngassam; Ariane Nkamgna; Mesmin Y Dehayem; François F Kaze; Andre P Kengne; Jean C Mbanya
Dans: Journal of clinical hypertension (Greenwich, Conn.), vol. 21, iss. 7, p. 1002-1008, 2019, ISSN: 1751-7176.
Résumé | Liens | BibTeX | Étiquettes: amlodipine, hypertension management, indapamide, perindopril, sub-Saharan African, type 2 diabetes
@article{Sobngwi2019,
title = {Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blinded randomized controlled trial.},
author = {Eugene Sobngwi and Liliane Mfeukeu-Kuate and Merveille Kouam and Aurel T Tankeu and Chris N Nganou-Gnindjio and Ba Hamadou and Martine Etoa and Eliane Ngassam and Ariane Nkamgna and Mesmin Y Dehayem and François F Kaze and Andre P Kengne and Jean C Mbanya},
url = {http://www.ncbi.nlm.nih.gov/pubmed/31175711},
doi = {10.1111/jch.13557},
issn = {1751-7176},
year = {2019},
date = {2019-01-01},
journal = {Journal of clinical hypertension (Greenwich, Conn.)},
volume = {21},
issue = {7},
pages = {1002-1008},
abstract = {Poor blood pressure (BP) control contributes to complications in sub-Saharan African (SSA) type 2 diabetic individuals. Experts have advocated the use of combination therapies for effective BP control in these patients. The suggested combinations should include a RAAS antagonist and either a CCB or a thiazide diuretic; however, their efficacy is yet to be established in SSA. We investigated the short-term effects of two combination therapies on BP control in SSA type 2 diabetic individuals. This was a double-blinded randomized controlled trial conducted at the Yaoundé Central Hospital (Cameroon) from October 2016 to May 2017. We included type 2 diabetic patients, newly diagnosed for hypertension. After baseline assessment and 24-hour ABPM, participants were allocated to receive either a fixed combination of perindopril + amlodipine or perindopril + indapamide for 42 days. Data analyses followed the intention-to-treat principle. We included fifteen participants (8 being females) in each group. Both combinations provided good circadian BP control after 6 weeks with similar efficacy. Twenty-four-hour SBP dropped from 144 to 145 mm Hg vs 128 to 126 mm Hg with perindopril-amlodipine and perindopril-indapamide, respectively (P = 0.003 for both groups). Twenty-four-hour DBP dropped from 85 to 78 mm Hg (P = 0.013) vs 89 to 79 mm Hg (P = 0.006) in the same respective groups. No significant adverse effect was reported. A fixed initial combination of perindopril-amlodipine or perindopril-indapamide achieved similar effective BP control after 6 weeks in SSA type 2 diabetic individuals with newly diagnosed hypertension. Therefore, these combinations can be used interchangeably in this indication.},
keywords = {amlodipine, hypertension management, indapamide, perindopril, sub-Saharan African, type 2 diabetes},
pubstate = {published},
tppubtype = {article}
}
Poor blood pressure (BP) control contributes to complications in sub-Saharan African (SSA) type 2 diabetic individuals. Experts have advocated the use of combination therapies for effective BP control in these patients. The suggested combinations should include a RAAS antagonist and either a CCB or a thiazide diuretic; however, their efficacy is yet to be established in SSA. We investigated the short-term effects of two combination therapies on BP control in SSA type 2 diabetic individuals. This was a double-blinded randomized controlled trial conducted at the Yaoundé Central Hospital (Cameroon) from October 2016 to May 2017. We included type 2 diabetic patients, newly diagnosed for hypertension. After baseline assessment and 24-hour ABPM, participants were allocated to receive either a fixed combination of perindopril + amlodipine or perindopril + indapamide for 42 days. Data analyses followed the intention-to-treat principle. We included fifteen participants (8 being females) in each group. Both combinations provided good circadian BP control after 6 weeks with similar efficacy. Twenty-four-hour SBP dropped from 144 to 145 mm Hg vs 128 to 126 mm Hg with perindopril-amlodipine and perindopril-indapamide, respectively (P = 0.003 for both groups). Twenty-four-hour DBP dropped from 85 to 78 mm Hg (P = 0.013) vs 89 to 79 mm Hg (P = 0.006) in the same respective groups. No significant adverse effect was reported. A fixed initial combination of perindopril-amlodipine or perindopril-indapamide achieved similar effective BP control after 6 weeks in SSA type 2 diabetic individuals with newly diagnosed hypertension. Therefore, these combinations can be used interchangeably in this indication.